Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 172Rituximab 157Specimen Handling 116Biopsy 93Magnetic Resonance Spectroscopy 90Vincristine 89Doxorubicin 83Prednisone 81fludarabine 70venetoclax 67obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 46acalabrutinib 43Etoposide 41blinatumomab 40CT-P10 39Bendamustine Hydrochloride 37fludarabine phosphate 33Gemcitabine 33prednylidene 32Calcium Dobesilate 32deltacortene 31zanubrutinib 30pembrolizumab 29glofitamab 28Nivolumab 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ofatumumab × Lymphoid × 90 days × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT02135133 2026-03-17

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡